Advanced Biomed Inc. Files Amendment to S-1 Registration Statement

TL;DR

<b>Advanced Biomed Inc. has filed an amendment to its S-1 registration statement, indicating its status as a smaller reporting company.</b>

AI Summary

Advanced Biomed Inc. (ADVB) filed a Amended IPO Registration (S-1/A) with the SEC on January 9, 2024. Advanced Biomed Inc. filed an amendment (S-1/A) to its registration statement on January 9, 2024. The company is incorporated in Nevada and operates in the Medical Laboratories sector (SIC 8071). Principal executive offices are located at 689-87 Xiaodong Road, Yongkang District, Tainan, Taiwan. The filing indicates Advanced Biomed Inc. is a smaller reporting company and a non-accelerated filer. The registration statement number is 333-272110.

Why It Matters

For investors and stakeholders tracking Advanced Biomed Inc., this filing contains several important signals. This amendment provides updated information for potential investors regarding the company's structure and regulatory filings. As a smaller reporting company, Advanced Biomed Inc. may have different disclosure requirements compared to larger filers, impacting investor analysis.

Risk Assessment

Risk Level: low — Advanced Biomed Inc. shows low risk based on this filing. The risk is low as this is a routine amendment to a registration statement, with no immediate financial or operational changes disclosed.

Analyst Insight

Monitor future filings for details on the proposed public offering and the company's financial performance.

Key Numbers

• 2024-01-09 — Filing Date (Date of S-1/A filing)
• 333-272110 — Registration Number (SEC registration number for the offering)
• 8071 — SIC Code (Standard Industrial Classification for Medical Laboratories)
• 0001575872-24-000031 — Accession Number (Unique identifier for the filing)

Key Players & Entities

• Advanced Biomed Inc. (company) — Registrant name
• 2024-01-09 (date) — Filing date
• 333-272110 (registration_number) — SEC registration number
• 8071 (sic_code) — Standard Industrial Classification Code
• NV (state) — State of incorporation
• Cogency Global Inc. (company) — Agent for service
• VCL Law LLP (company) — Legal counsel
• Ortoli Rosenstadt LLP (company) — Legal counsel

Forward-Looking Statements

• Advanced Biomed Inc. will complete its initial public offering (IPO) (Advanced Biomed Inc.) — medium confidence, target: 2024-06-30
• The company's stock will experience high volatility upon listing (Advanced Biomed Inc.) — medium confidence, target: 2024-12-31

FAQ

Industry Context

The company operates within the medical laboratories industry, providing diagnostic and testing services.

Regulatory Implications

The filing is made under the Securities Act of 1933, requiring specific disclosures for public offerings.

What Investors Should Do

1. Review the full S-1/A filing for details on the securities being registered.
2. Track subsequent amendments or filings for updates on the offering's progress.
3. Research the company's business model and market position within the medical laboratory sector.

Year-Over-Year Comparison

This is an amendment to a previously filed registration statement, providing updated information rather than a new initial filing.

Key Financial Figures

• $0.001 — 0,000 shares of common stock, par value $0.001 per share, of Advanced Biomed Inc. We e
• $4.00 — l public offering price will be between $4.00 to $5.00 per share of common stock. Pri
• $5.00 — offering price will be between $4.00 to $5.00 per share of common stock. Prior to thi

Filing Documents

• vc034_s1a.htm (S-1/A) — 2023KB
• vc034_ex15-1.htm (EX-15.1) — 4KB
• vc034_ex23-1.htm (EX-23.1) — 4KB
• vc034_ex99-8.htm (EX-99.8) — 25KB
• vc034_img01.jpg (GRAPHIC) — 21KB
• vc034_img02.jpg (GRAPHIC) — 32KB
• vc034_img03.jpg (GRAPHIC) — 22KB
• vc034_img04.jpg (GRAPHIC) — 57KB
• vc034_img05.jpg (GRAPHIC) — 85KB
• vc034_img06.jpg (GRAPHIC) — 7KB
• vc034_img07.jpg (GRAPHIC) — 111KB
• vc034_img08.jpg (GRAPHIC) — 67KB
• vc034_img09.jpg (GRAPHIC) — 109KB
• vc034_img10.jpg (GRAPHIC) — 67KB
• vc034_img11.jpg (GRAPHIC) — 57KB
• vc034_img12.jpg (GRAPHIC) — 53KB
• vc034_img13.jpg (GRAPHIC) — 69KB
• vc034_img14.jpg (GRAPHIC) — 26KB
• vc034_img15.jpg (GRAPHIC) — 43KB
• vc034_img16.jpg (GRAPHIC) — 23KB
• vc034_img17.jpg (GRAPHIC) — 10KB
• vc034_ex15-1img01.jpg (GRAPHIC) — 26KB
• vc034_ex15-1img02.jpg (GRAPHIC) — 4KB
• vc034_ex15-1img03.jpg (GRAPHIC) — 10KB
• vc034_ex23-1img01.jpg (GRAPHIC) — 26KB
• vc034_ex23-1img02.jpg (GRAPHIC) — 4KB
• vc034_ex23-1img03.jpg (GRAPHIC) — 10KB
• 0001575872-24-000031.txt (&nbsp;) — 3350KB

From the Filing

As filed with the Securities and Exchange Commission on January 9, 2024. Registration No. 333-272110 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 10 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Advanced Biomed Inc. (Exact name of registrant as specified in its charter) Nevada 8071 87-2177170 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 689-87 Xiaodong Road, Yongkang District Tainan, Taiwan Tel: 886-6-3121716 (Address, including zip code, and telephone number, including area code, of registrant&rsquo;s principal executive offices) Cogency Global Inc. 122 East 42nd Street, 18th Floor New York, NY 10168 (212) 947-7200 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies of all communications to: Fang Liu, Esq. VCL Law LLP William S. Rosenstadt, Esq. Mengyi &ldquo;Jason&rdquo; Ye, Esq. 1945 Old Gallows Road Ortoli Rosenstadt LLP Suite 260 366 Madison Avenue, 3rd Floor Vienna, VA 22182 New York, NY 10017 Telephone: (703) 919-7285 Telephone: (212) 588-0022 Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box: If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2 of the Exchange Act. Large Accelerated Filer Accelerated Filer Non-Accelerated Filer Smaller Reporting Company Emerging Growth Company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall hereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine. The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the SEC is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. dated January 9, 2024 PRELIMINARY PROSPECTUS Advanced Biomed Inc. 25,000,000 Shares of Common Stock This prospectus relates to the offer and sale of 25,000,000 shares of common stock, par value $0.001 per share, of Advanced Biomed Inc. We expect that the initial public offering price will be between $4.00 to $5.00 per share of common stock. Prior to this offering, there has been no public market for our common stock. We have applied to list our common stock on the Nasdaq Capital Market under the symbol &ldquo;ADVB.&rdquo; We believe that upon the completion of the offering contemplated by this prospectus, we will meet the standards for listing on the Nasdaq Capital Market. We cannot guarantee that we will be successful in listing our common stock on the Nasdaq Capital Market; however, we will not complete this offering unless we are so listed. Advanced Biomed Inc. (&ldquo;Advanced Biomed&rdquo;) is not an operating company but a holding company incorporated in the State of Nevada. Substantially all of the business operations are conducted in Taiwan by our Taiwan subsidiary. And we also have a subsidiary in Hong Kong a

View Full Filing

View this S-1/A filing on SEC EDGAR